Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
Description: Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the United States, Europe, and internationally. The company?s products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, and MONOVISC for the treatment of osteoarthritis of the knee and joints; Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells that is used in connection with soft tissue regeneration; Hyalonect, a woven gauze used as a graft wrap; Hyaloss used to mix blood/bone grafts to form a paste for bone regeneration; and Hyaloglide, an ACP gel used in tenolysis treatment. The company?s dermal products include wound care products that comprise Hyalomatrix and Hyalofill, for treatment of complex wounds, such as burns and ulcers; Hyalograft 3D and Laserskin scaffolds for use in connection with the regen
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||2.07||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-40.93%||Sales Growth - Q/Q||-33.26%||P/E||21.89|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||13.56%||ROE||14.74%||ROI|
|Current Ratio||23.7||Quick Ratio||21.67||Long Term Debt/Equity||Debt Ratio||0.03|
|Gross Margin||76.03%||Operating Margin||49.46%||Net Profit Margin||30.77%||Dividend Payout Ratio|
|Cash From Financing Activities||1.9 M||Cash From Investing Activities||-6.01 M||Cash From Operating Activities||3.98 M||Gross Profit||17.63 M|
|Net Profit||7.82 M||Operating Profit||12.43 M||Total Assets||208.01 M||Total Current Assets||155.73 M|
|Total Current Liabilities||7.96 M||Total Debt||Total Liabilities||17.44 M||Total Revenue||22.9 M|
|High 52 week||68.43||Low 52 week||43.78||Last close||43.98||Last change||-0.97%|
|RSI||32.42||Average true range||1.17||Beta||0.54||Volume||53.19 K|
|Simple moving average 20 days||-4.63%||Simple moving average 50 days||-13.01%||Simple moving average 200 days||-18.62%|
|Performance Week||-3.4%||Performance Month||-10.65%||Performance Quart||-29.55%||Performance Half||-26.2%|
|Performance Year||-1.96%||Performance Year-to-date||-18.42%||Volatility daily||1.44%||Volatility weekly||3.21%|
|Volatility monthly||6.58%||Volatility yearly||22.81%||Relative Volume||229.99%||Average Volume||106.58 K|
|New High||New Low|
2019-03-18 08:30:00 | Anika Appoints Robert Richard, Ph.D. as Vice President of Research and Development
2019-03-11 16:05:00 | Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting
2019-03-06 02:20:36 | Edited Transcript of ANIK earnings conference call or presentation 27-Feb-04 4:00pm GMT
2019-03-06 02:18:14 | Edited Transcript of ANIK earnings conference call or presentation 17-Mar-10 1:00pm GMT
2019-02-22 09:46:10 | Anika Therapeutics ANIK Q4 2018 Earnings Conference Call Transcript
2019-02-22 00:10:42 | Edited Transcript of ANIK earnings conference call or presentation 21-Feb-19 10:00pm GMT
2019-02-21 18:55:11 | Anika Therapeutics ANIK Q4 Earnings and Revenues Top Estimates
2019-02-21 18:01:32 | Anika: 4Q Earnings Snapshot
2019-02-21 16:05:00 | Anika Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-20 12:05:41 | How Financially Strong Is Anika Therapeutics, Inc. NASDAQ:ANIK?
2019-02-01 07:35:00 | New Research: Key Drivers of Growth for Cisco, Landstar System, Central Garden & Pet, Anika Therapeutics, Hibbett Sports, and MoneyGram International — Factors of Influence, Major Initiatives and Sustained Production
2019-01-21 11:58:50 | When Should You Buy Anika Therapeutics, Inc. NASDAQ:ANIK?
2019-01-14 09:30:02 | ANIK or TECH: Which Is the Better Value Stock Right Now?
2018-12-27 15:13:09 | 6 Undervalued Stocks With Positive Earnings Growth Estimates
2018-12-24 09:26:02 | Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder
2018-12-23 12:00:52 | Hedge Funds Are Dumping Anika Therapeutics, Inc. ANIK
2018-12-21 09:19:02 | Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead
2018-12-20 12:39:53 | Do You Know What Anika Therapeutics, Inc.’s NASDAQ:ANIK P/E Ratio Means?
2018-12-17 09:30:02 | ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?
2018-12-14 07:59:12 | 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
2018-12-14 07:57:12 | Anika Therapeutics Enters Oversold Territory
2018-12-10 08:44:01 | Why Abeona Therapeutics ABEO Could Be Positioned for a Slump
2018-12-04 16:05:00 | Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX
2018-11-13 14:43:07 | Is Anika Therapeutics Inc’s NASDAQ:ANIK ROE Of 7.5% Concerning?
2018-11-02 08:55:00 | New Research: Key Drivers of Growth for Edison International, NuVasive, LogMein, Anika Therapeutics, First Industrial Realty Trust, and ON Semiconductor — Factors of Influence, Major Initiatives and Sustained Production
2018-10-29 09:30:01 | ANIK vs. RGNX: Which Stock Should Value Investors Buy Now?
2018-10-25 10:16:01 | Edited Transcript of ANIK earnings conference call or presentation 24-Oct-18 9:00pm GMT
2018-10-24 20:02:55 | Anika Therapeutics Inc ANIK Q3 2018 Earnings Conference Call Transcript
2018-10-24 17:25:09 | Anika Therapeutics ANIK Q3 Earnings Beat Estimates
2018-10-24 16:17:50 | Anika: 3Q Earnings Snapshot
2018-10-24 16:05:00 | Anika Reports Third Quarter 2018 Financial Results
2018-10-24 08:30:00 | Susan Vogt Appointed to Board of Directors of Anika Therapeutics
2018-10-22 11:22:03 | What's in Store for Anika Therapeutics ANIK in Q3 Earnings?
2018-10-17 10:32:02 | Anika Therapeutics ANIK Q3 Earnings Preview: What to Look Out For
2018-10-11 08:15:00 | Market Trends Toward New Normal in Park Hotels & Resorts, Safety Insurance Group, Cincinnati Financial, Anika Therapeutics, CME Group, and Midstates Petroleum — Emerging Consolidated Expectations, Analyst Ratings
2018-09-28 10:58:02 | Ultragenyx Reports Top-line Data From Gene Therapy Candidate
2018-09-27 08:49:12 | AVEO Pharmaceuticals AVEO Soars: Stock Adds 6.4% in Session
2018-09-26 08:59:12 | Novavax NVAX Catches Eye: Stock Jumps 7.6%
2018-09-25 11:18:03 | Arena ARNA Posts Favorable Top-Line Data on Pain Candidate
2018-09-25 10:52:02 | FDA Lifts Clinical Hold on Epizyme's Lead Candidate's Study
2018-09-25 10:44:02 | FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program
2018-09-25 08:50:12 | Alexion Pharmaceuticals ALXN Surges: Stock Moves 5.3% Higher
2018-09-05 16:05:00 | Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors